Novo Nordisk A/S is following in rival Eli Lilly & Co.’s footsteps by selling its hit weight-loss drug Wegovy directly to US ...
Novo Nordisk is cutting prices on weight-loss drug Wegovy, a week after Eli Lilly did the same for rival Zepbound.
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS ...
Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...
Many Marylanders struggle with obesity but cannot get access to weight loss medications because insurance will not pay for ...
Rutgers University recently launched the Center for NeuroMetabolism, which aims to address the weight loss and health ...
Ozempic, Mounjaro and Wegovy may not be the lightbulb, jet airplane or internet, but their impact is expected to be so ...
Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range ...
Whether you have type 2 diabetes, obesity or just a few extra pounds that you’d like some help shedding, chances are you’re ...
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
WESH 2's Jason Guy and Orlando Health Weight Loss & Bariatric Surgery Institute surgeon, Dr. Muhammad Ghanem, discuss potential influences on the downward trend ...
The Food and Drug Administration on Friday said the shortage of Novo Nordisk's weight-loss and diabetes drugs Wegovy and Ozempic is resolved, a move that could limit the availability of cheaper ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results